BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26335130)

  • 1. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
    Shapira M; Raanani H; Feldman B; Srebnik N; Dereck-Haim S; Manela D; Brenghausen M; Geva-Lerner L; Friedman E; Levi-Lahad E; Goldberg D; Perri T; Eldar-Geva T; Meirow D
    Fertil Steril; 2015 Nov; 104(5):1162-7. PubMed ID: 26335130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD.
    Derks-Smeets IAP; van Tilborg TC; van Montfoort A; Smits L; Torrance HL; Meijer-Hoogeveen M; Broekmans F; Dreesen JCFM; Paulussen ADC; Tjan-Heijnen VCG; Homminga I; van den Berg MMJ; Ausems MGEM; de Rycke M; de Die-Smulders CEM; Verpoest W; van Golde R
    J Assist Reprod Genet; 2017 Nov; 34(11):1475-1482. PubMed ID: 28831696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation.
    Gunnala V; Fields J; Irani M; D'Angelo D; Xu K; Schattman G; Rosenwaks Z
    Fertil Steril; 2019 Feb; 111(2):363-371. PubMed ID: 30527950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal.
    Avraham S; Almog B; Reches A; Zakar L; Malcov M; Sokolov A; Alpern S; Azem F
    Hum Reprod; 2017 Jul; 32(7):1508-1511. PubMed ID: 28472405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA mutations and reproduction.
    Daum H; Peretz T; Laufer N
    Fertil Steril; 2018 Jan; 109(1):33-38. PubMed ID: 29307397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
    Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
    Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
    Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
    Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
    Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
    Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients.
    Michaan N; Ben-David G; Ben-Yosef D; Almog B; Many A; Pauzner D; Lessing JB; Amit A; Azem F
    Eur J Obstet Gynecol Reprod Biol; 2010 Apr; 149(2):175-7. PubMed ID: 20074845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, independent from ovarian reserve status, is the main prognostic factor in natural cycle in vitro fertilization.
    González-Foruria I; Peñarrubia J; Borràs A; Manau D; Casals G; Peralta S; Creus M; Ferreri J; Vidal E; Carmona F; Balasch J; Fàbregues F
    Fertil Steril; 2016 Aug; 106(2):342-347.e2. PubMed ID: 27117376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gronwald J; Glass K; Rosen B; Karlan B; Tung N; Neuhausen SL; Moller P; Ainsworth P; Sun P; Narod SA; Lubinski J; Kotsopoulos J;
    Fertil Steril; 2016 Mar; 105(3):781-785. PubMed ID: 26698676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors.
    Derks-Smeets IA; de Die-Smulders CE; Mackens S; van Golde R; Paulussen AD; Dreesen J; Tournaye H; Verdyck P; Tjan-Heijnen VC; Meijer-Hoogeveen M; De Greve J; Geraedts J; De Rycke M; Bonduelle M; Verpoest WM
    Breast Cancer Res Treat; 2014 Jun; 145(3):673-81. PubMed ID: 24748567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the time interval between hysteroscopic polypectomy and start of in vitro fertilization affect outcomes?
    Pereira N; Amrane S; Estes JL; Lekovich JP; Elias RT; Chung PH; Rosenwaks Z
    Fertil Steril; 2016 Feb; 105(2):539-44.e1. PubMed ID: 26604066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fertility preservation in BRCA mutation carriers-efficacy and safety issues: a review.
    Zhang X; Niu J; Che T; Zhu Y; Zhang H; Qu J
    Reprod Biol Endocrinol; 2020 Feb; 18(1):11. PubMed ID: 32070378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Female cystic fibrosis mutation carriers and assisted reproductive technology: does carrier status affect reproductive outcomes?
    VanWort TA; Lee JA; Karvir H; Whitehouse MC; Beim PY; Copperman AB
    Fertil Steril; 2014 Nov; 102(5):1324-30. PubMed ID: 25217870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IVF for fertility preservation in breast cancer patients--efficacy and safety issues.
    Shapira M; Raanani H; Meirow D
    J Assist Reprod Genet; 2015 Aug; 32(8):1171-8. PubMed ID: 26126877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy.
    Srebnik N; Margalioth EJ; Rabinowitz R; Varshaver I; Altarescu G; Renbaum P; Levi-Lahad E; Weintraub A; Eldar-Geva T
    Reprod Biomed Online; 2014 Jul; 29(1):94-101. PubMed ID: 24813161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live-birth rates in very poor prognosis patients, who are defined as poor responders under the Bologna criteria, with nonelective single embryo, two-embryo, and three or more embryos transferred.
    Gleicher N; Vega MV; Darmon SK; Weghofer A; Wu YG; Wang Q; Zhang L; Albertini DF; Barad DH; Kushnir VA
    Fertil Steril; 2015 Dec; 104(6):1435-41. PubMed ID: 26348275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproductive outcomes after in vitro fertilization treatment in a cohort of Danish women transplanted with cryopreserved ovarian tissue.
    Dueholm Hjorth IM; Kristensen SG; Dueholm M; Humaidan P
    Fertil Steril; 2020 Aug; 114(2):379-387. PubMed ID: 32624219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CGG repeat number on ovarian response among fragile X premutation carriers undergoing preimplantation genetic diagnosis.
    Bibi G; Malcov M; Yuval Y; Reches A; Ben-Yosef D; Almog B; Amit A; Azem F
    Fertil Steril; 2010 Aug; 94(3):869-74. PubMed ID: 19481741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.